GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
But the company still has a lot to prove with ERAS-0015.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
